EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Critical challenges and advances in recombinant adeno‐associated virus (rAAV) biomanufacturing

Qiang Fu, Ashli Polanco, Yong Suk Lee, Seongkyu Yoon iD

Biotechnology and Bioengineering · 2023-09 · 120 (9) · 2601-2621

DOI: 10.1002/bit.28412 ↗

At a glance

Übersichtsarbeit in Biotechnology and Bioengineering, 2023-05. Written by Qiang Fu and 3 co-authors. Institution: Department of Biomedical Engineering and Biotechnology, The University of Massachusetts Lowell, Lowell, Massachusetts, USA. Major MEDLINE topics: Dependovirus, Genetic Vectors. Cited 85 times so far (Crossref); 186 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Gene therapy is a promising therapeutic approach for genetic and acquired diseases nowadays. Among DNA delivery vectors, recombinant adeno‐associated virus (rAAV) is one of the most effective and safest vectors used in commercial drugs and clinical trials. However, the current yield of rAAV biomanufacturing lags behind the necessary dosages for clinical and commercial use, which embodies a concentrated reflection of low productivity of rAAV from host cells, difficult scalability of the rAAV‐producing bioprocess, and high levels of impurities materialized during production. Those issues directly impact the price of gene therapy medicine in the market, limiting most patients’ access to gene therapy. In this context, the current practices and several critical challenges associated with rAAV gene therapy bioprocesses are reviewed, followed by a discussion of recent advances in rAAV‐mediated gene therapy and other therapeutic biological fields that could improve biomanufacturing if these advances are integrated effectively into the current systems. This review aims to provide the current state‐of‐the‐art technology and perspectives to enhance the productivity of rAAV while reducing impurities during production of rAAV.

Subjects

MeSH terms (MEDLINE)

DependovirusGenetic VectorsHumansGenetic Therapy

Author keywords

capsid recoverycontinuous manufacturinggene therapy manufacturingin silico modelinginducible systemmultiomicsrecombinant AAV (rAAV)

Authors and institutions

  • Department of Biomedical Engineering and Biotechnology, The University of Massachusetts Lowell, Lowell, Massachusetts, USA.
  • Department of Chemical Engineering, The University of Massachusetts Lowell, Lowell, Massachusetts, USA.
  • Department of Pharmaceutical Sciences, The University of Massachusetts Lowell, Lowell, Massachusetts, USA.

ORCID profiles: Seongkyu Yoon

Cite

APA

Fu, Q., Polanco, A., Lee, Y. S., & Yoon, S. (2023). Critical challenges and advances in recombinant adeno‐associated virus (rAAV) biomanufacturing. Biotechnology and Bioengineering, 120(9), 2601-2621. https://doi.org/10.1002/bit.28412

Vancouver

Fu Q, Polanco A, Lee YS, Yoon S. Critical challenges and advances in recombinant adeno‐associated virus (rAAV) biomanufacturing. Biotechnology and Bioengineering. 2023;120(9):2601-2621. doi:10.1002/bit.28412

BibTeX
@article{Fu2023,
  author = {Fu, Qiang and Polanco, Ashli and Lee, Yong Suk and Yoon, Seongkyu},
  title = {Critical challenges and advances in recombinant adeno‐associated virus (rAAV) biomanufacturing},
  journal = {Biotechnology and Bioengineering},
  year = {2023},
  volume = {120},
  number = {9},
  pages = {2601--2621},
  doi = {10.1002/bit.28412}
}
Start for free →